Preoperative Systemic Therapy Versus Upfront Surgery in HER2-Positive Breast Cancer in the Real World
PurposeTo compare survival in different strategies, preoperative systemic treatment versus upfront surgery, in HER2-positive early breast cancer patients in the real world.MethodsAccording to the actual upfront treatment, eligible patients from 2012 to 2015 were classified as preoperative systemic t...
Main Authors: | , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-07-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.704842/full |
id |
doaj-fb6652e5919e40e9b4f500cb7e5fd595 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Xingfei Yu Chen Wang Yabing Zheng Beibei Miao Jiejie Hu Xiying Shao Liming Sheng Juan Lin Yuqin Ding Haojun Xuan Yingying Ding Lijie Gong Weiliang Feng Chengdong Qin Daobao Chen Yang Yu Hongjian Yang |
spellingShingle |
Xingfei Yu Chen Wang Yabing Zheng Beibei Miao Jiejie Hu Xiying Shao Liming Sheng Juan Lin Yuqin Ding Haojun Xuan Yingying Ding Lijie Gong Weiliang Feng Chengdong Qin Daobao Chen Yang Yu Hongjian Yang Preoperative Systemic Therapy Versus Upfront Surgery in HER2-Positive Breast Cancer in the Real World Frontiers in Oncology human epidermal growth factor receptor 2 breast cancer preoperative systemic treatment surgery real world |
author_facet |
Xingfei Yu Chen Wang Yabing Zheng Beibei Miao Jiejie Hu Xiying Shao Liming Sheng Juan Lin Yuqin Ding Haojun Xuan Yingying Ding Lijie Gong Weiliang Feng Chengdong Qin Daobao Chen Yang Yu Hongjian Yang |
author_sort |
Xingfei Yu |
title |
Preoperative Systemic Therapy Versus Upfront Surgery in HER2-Positive Breast Cancer in the Real World |
title_short |
Preoperative Systemic Therapy Versus Upfront Surgery in HER2-Positive Breast Cancer in the Real World |
title_full |
Preoperative Systemic Therapy Versus Upfront Surgery in HER2-Positive Breast Cancer in the Real World |
title_fullStr |
Preoperative Systemic Therapy Versus Upfront Surgery in HER2-Positive Breast Cancer in the Real World |
title_full_unstemmed |
Preoperative Systemic Therapy Versus Upfront Surgery in HER2-Positive Breast Cancer in the Real World |
title_sort |
preoperative systemic therapy versus upfront surgery in her2-positive breast cancer in the real world |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Oncology |
issn |
2234-943X |
publishDate |
2021-07-01 |
description |
PurposeTo compare survival in different strategies, preoperative systemic treatment versus upfront surgery, in HER2-positive early breast cancer patients in the real world.MethodsAccording to the actual upfront treatment, eligible patients from 2012 to 2015 were classified as preoperative systemic treatment or upfront surgery group prospectively. The primary endpoint is disease-free survival; the second endpoint is overall survival. All the outcomes were examined in the propensity score matching model and inverse probability of treatment weighting model.ResultsIncluded in the analysis were 1,067 patients (215 in the preoperative systemic treatment group, 852 in the upfront surgery group). In the propensity score matching model (matching at 1:1 ratio), the disease-free survival of the preoperative systemic treatment group was significantly higher than that of the upfront surgery group (hazard ratio, 0.572, 95%CI, 0.371–0.881, P, 0.012). In the inverse probability of treatment weighting model, there was no significant difference in disease-free survival between the two groups (hazard ratio, 0.946, 95%CI, 0.763–1.172, P, 0.609). For overall survival, there was no significant difference between the two groups.ConclusionThe HER2-positive patients who accepted preoperative systemic treatment had better disease-free survival than those who underwent upfront surgery by real-world statistic methods.Clinical Trial RegistrationClinicaltrials.gov, identifier NCT04249440. |
topic |
human epidermal growth factor receptor 2 breast cancer preoperative systemic treatment surgery real world |
url |
https://www.frontiersin.org/articles/10.3389/fonc.2021.704842/full |
work_keys_str_mv |
AT xingfeiyu preoperativesystemictherapyversusupfrontsurgeryinher2positivebreastcancerintherealworld AT chenwang preoperativesystemictherapyversusupfrontsurgeryinher2positivebreastcancerintherealworld AT yabingzheng preoperativesystemictherapyversusupfrontsurgeryinher2positivebreastcancerintherealworld AT beibeimiao preoperativesystemictherapyversusupfrontsurgeryinher2positivebreastcancerintherealworld AT jiejiehu preoperativesystemictherapyversusupfrontsurgeryinher2positivebreastcancerintherealworld AT xiyingshao preoperativesystemictherapyversusupfrontsurgeryinher2positivebreastcancerintherealworld AT limingsheng preoperativesystemictherapyversusupfrontsurgeryinher2positivebreastcancerintherealworld AT juanlin preoperativesystemictherapyversusupfrontsurgeryinher2positivebreastcancerintherealworld AT yuqinding preoperativesystemictherapyversusupfrontsurgeryinher2positivebreastcancerintherealworld AT haojunxuan preoperativesystemictherapyversusupfrontsurgeryinher2positivebreastcancerintherealworld AT yingyingding preoperativesystemictherapyversusupfrontsurgeryinher2positivebreastcancerintherealworld AT lijiegong preoperativesystemictherapyversusupfrontsurgeryinher2positivebreastcancerintherealworld AT weiliangfeng preoperativesystemictherapyversusupfrontsurgeryinher2positivebreastcancerintherealworld AT chengdongqin preoperativesystemictherapyversusupfrontsurgeryinher2positivebreastcancerintherealworld AT daobaochen preoperativesystemictherapyversusupfrontsurgeryinher2positivebreastcancerintherealworld AT yangyu preoperativesystemictherapyversusupfrontsurgeryinher2positivebreastcancerintherealworld AT hongjianyang preoperativesystemictherapyversusupfrontsurgeryinher2positivebreastcancerintherealworld |
_version_ |
1721268125332144128 |
spelling |
doaj-fb6652e5919e40e9b4f500cb7e5fd5952021-07-28T15:15:43ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-07-011110.3389/fonc.2021.704842704842Preoperative Systemic Therapy Versus Upfront Surgery in HER2-Positive Breast Cancer in the Real WorldXingfei Yu0Chen Wang1Yabing Zheng2Beibei Miao3Jiejie Hu4Xiying Shao5Liming Sheng6Juan Lin7Yuqin Ding8Haojun Xuan9Yingying Ding10Lijie Gong11Weiliang Feng12Chengdong Qin13Daobao Chen14Yang Yu15Hongjian Yang16Department of Breast Tumor Surgery, Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, ChinaDepartment of Breast Tumor Surgery, Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, ChinaDepartment of Medical Oncology, Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, ChinaTaizhou Cancer Hospital, Taizhou, ChinaDepartment of Breast Tumor Surgery, Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, ChinaDepartment of Medical Oncology, Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, ChinaDepartment of Radiotherapy, Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, ChinaDepartment of Radiotherapy, Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, ChinaDepartment of Breast Tumor Surgery, Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, ChinaDepartment of Breast Tumor Surgery, Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, ChinaTaizhou Cancer Hospital, Taizhou, ChinaDepartment of Breast Tumor Surgery, Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, ChinaDepartment of Breast Tumor Surgery, Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, ChinaDepartment of Breast Tumor Surgery, Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, ChinaDepartment of Breast Tumor Surgery, Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, ChinaDepartment of Breast Tumor Surgery, Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, ChinaDepartment of Breast Tumor Surgery, Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, ChinaPurposeTo compare survival in different strategies, preoperative systemic treatment versus upfront surgery, in HER2-positive early breast cancer patients in the real world.MethodsAccording to the actual upfront treatment, eligible patients from 2012 to 2015 were classified as preoperative systemic treatment or upfront surgery group prospectively. The primary endpoint is disease-free survival; the second endpoint is overall survival. All the outcomes were examined in the propensity score matching model and inverse probability of treatment weighting model.ResultsIncluded in the analysis were 1,067 patients (215 in the preoperative systemic treatment group, 852 in the upfront surgery group). In the propensity score matching model (matching at 1:1 ratio), the disease-free survival of the preoperative systemic treatment group was significantly higher than that of the upfront surgery group (hazard ratio, 0.572, 95%CI, 0.371–0.881, P, 0.012). In the inverse probability of treatment weighting model, there was no significant difference in disease-free survival between the two groups (hazard ratio, 0.946, 95%CI, 0.763–1.172, P, 0.609). For overall survival, there was no significant difference between the two groups.ConclusionThe HER2-positive patients who accepted preoperative systemic treatment had better disease-free survival than those who underwent upfront surgery by real-world statistic methods.Clinical Trial RegistrationClinicaltrials.gov, identifier NCT04249440.https://www.frontiersin.org/articles/10.3389/fonc.2021.704842/fullhuman epidermal growth factor receptor 2breast cancerpreoperative systemic treatmentsurgeryreal world |